PKD1 and autosomal dominant polycystic kidney disease: Based on drug repositioning, Asawa et al. developed a high-throughput screening platform for ADPKD (13) that employs Pkd1-null postnatal cells of proximal tubule origin, Pkd1-null mouse embryonic kidney cells of collecting duct origin (MEK-null), and Pkd1−/− human kidney epithelial cells in order to evaluate a set of 8814 approved drugs and studied compounds principally having anti-neoplastic usage.